US Patent 8,003,673 (Daptomycin in Lactated Ringer’s for Biofilms): Scope, Claim Coverage, and Landscape
US Patent 8,003,673 is directed to daptomycin-based treatment of biofilms using (i) daptomycin in lactated Ringer’s solution and (ii) daptomycin with calcium for device and catheter biofilm control, including catheter lock therapy. The claims define a method-and-kit framework with parameterized limitations around vehicle (lactated Ringer’s), exposure time, dosing frequency, and daptomycin concentration, plus device-specific embodiments (catheter lumens) and a catheter-lock exposure window (about 18 hours).
What do the independent claims cover?
Claim 1 (lactated Ringer’s vehicle; biofilm treatment method)
Claim 1 establishes the core composition-and-use concept:
- Method for treating a biofilm
- Providing a solution of daptomycin in lactated Ringer’s solution to the biofilm
This claim is broad in structure (biofilm is not limited to anatomic site or organism) but anchored by two required elements:
- The solute is daptomycin
- The solvent/vehicle is lactated Ringer’s
Claim 1 does not, on its face, require a device, a catheter, calcium, or a specific exposure duration or concentration. Those are added in dependent claims.
Claim 10 (daptomycin + calcium for device surface; catheter option)
Claim 10 defines a second coverage pillar:
- Method of treating or preventing a biofilm
- Exposing a surface of a device to a solution comprising daptomycin and calcium
This claim adds:
- device surface exposure (not limited to catheter)
- a formulation requirement: daptomycin + calcium (no explicit vehicle stated in Claim 10 itself, but later claims specify lactated Ringer’s)
Claims 11-12 narrow device geometry and exposure delivery using catheter-specific lock therapy.
Claim 20 (kit)
Claim 20 provides product form coverage:
- Kit for treatment of biofilm in a catheter
- comprising lactated Ringer’s solution having daptomycin in an amount sufficient to treat the biofilm
This is tied to catheter biofilm treatment and the lactated Ringer’s/daptomycin formulation, but does not specify concentration in the kit claim itself (concentration is provided in dependent claims in the method portion).
How do the dependent claims narrow scope (timing, dosing, concentration, device setting)?
Exposure duration and treatment regimen (Claims 2, 5, 6, 7, 17, 14)
The claim set introduces multiple timing and administration-frequency limitations:
- Claim 2: biofilm is treated for at least 30 minutes
- Claim 5: solution applied for about 30 minutes
- Claim 6: administered twice per day
- Claim 7: administered at least four times per day
- Claim 17: surface exposed for at least about 30 minutes with about 5 mg/mL daptomycin
For catheter lock therapy:
- Claim 14: catheter lock therapy exposes catheter surface to the solution for about 18 hours
Daptomycin concentration thresholds (Claims 8, 9, 13, 17)
The claims use explicit concentration floors and an anchored “about 5 mg/mL”:
- Claim 8: daptomycin concentration at least 1 mg/mL
- Claim 9: daptomycin concentration at least 5 mg/mL
- Claim 13: solution comprises about 5 mg/mL daptomycin plus physiological concentration of calcium
- Claim 17: solution comprises about 5 mg/mL daptomycin (in context of catheter + heparin flush; inner luminal surface)
Biofilm outcome limitation (Claim 4)
- Claim 4: biofilm is reduced and does not reoccur
This is an outcome-based functional limitation, increasing evidentiary burdens in enforcement (proof that recurrence does not occur) but still restricting claim scope to protocols with that effect.
Device and catheter-specific claim structure (Claims 10-12, 16-19)
The device-related claims create two layers: generic device surface exposure and catheter lumen lock therapy.
Device surface to catheter lumen exposure (Claims 11-12, 19)
- Claim 11: surface forms a portion of a catheter
- Claim 12: surface is an inner luminal surface of a catheter, exposed via catheter lock therapy
- Claim 19: method treats biofilm in a catheter; inner luminal surface; solution is about 5 mg/mL daptomycin in lactated Ringer’s solution
Catheter example + ancillary procedure (Claims 16, 18)
- Claim 16: further comprising a heparin flush of the catheter (in the context of Claim 11)
- Claim 18: catheter is a central venous catheter
- Claim 16’s practical effect: locks + flushing protocol is explicitly within dependent scope, which matters for infringement theories tied to clinical workflows.
Practical claim “coverage matrix” (what combinations trigger infringement risk)
Formulation and vehicle constraints
| Claim group |
Required formulation element(s) |
| Claims 1-9, 15, 19, 20 |
Daptomycin in lactated Ringer’s (at least by Claim 1; later claims quantify) |
| Claims 10-14, 13-17 |
Daptomycin + calcium (physiological calcium in Claim 13); later claims tie calcium to lactated Ringer’s in Claim 15 |
| Claim 15 |
daptomycin and lactated Ringer’s solution (positions lactated Ringer’s as the vehicle in the calcium/device framework) |
Delivery constraints
| Claim group |
Delivery constraint(s) |
| Claims 2, 5, 17 |
exposure at least ~30 minutes (with Claim 17 also requiring ~5 mg/mL) |
| Claims 6-7 |
twice daily or ≥ four times daily administration |
| Claims 12-14, 19 |
catheter lock therapy, inner luminal exposure; exposure window ~18 hours |
Concentration constraints
| Claim |
Minimum / stated concentration |
| Claim 8 |
≥ 1 mg/mL daptomycin |
| Claim 9 |
≥ 5 mg/mL daptomycin |
| Claim 13 |
~5 mg/mL daptomycin + physiological calcium |
| Claim 17 |
~5 mg/mL daptomycin (with catheter + exposure ≥ ~30 minutes and heparin flush in context) |
| Claim 19 |
~5 mg/mL daptomycin in lactated Ringer’s |
What is the core infringement “handle” for competitors?
The claims create two main “handle points” for enforcement and design-around analysis:
- Vehicle-based handle: daptomycin delivered in lactated Ringer’s solution to the biofilm (Claim 1; reinforced by Claim 15; kit Claim 20; catheter embodiment in Claim 19).
- Device-and-lock handle: catheter lumen exposure through catheter lock therapy using daptomycin + calcium (Claims 10-14; with inner luminal specificity in Claim 12 and the ~18-hour exposure in Claim 14; with ~5 mg/mL + lactated Ringer’s specified in Claim 19).
Dependent claims then tighten on:
- concentration (≥1 mg/mL; ≥5 mg/mL; about 5 mg/mL)
- time (about 30 minutes; ≥30 minutes; about 18 hours)
- dosing frequency (twice daily; ≥ four times daily)
- clinical workflow (heparin flush in Claim 16)
- outcome (no reoccurrence in Claim 4)
Where does the claim scope overlap across the two “pillars”?
Overlap is strongest where the claim set converges on about 5 mg/mL daptomycin and catheter lumen biofilm exposure:
- Claim 13 ties ~5 mg/mL + calcium (physiological) in the daptomycin+calcium device exposure framework.
- Claim 15 ties daptomycin device exposure to lactated Ringer’s.
- Claim 17 ties catheter workflows to ~5 mg/mL and ≥30 minutes, with heparin flush as an added element.
- Claim 19 is the direct convergence: catheter inner luminal surface with ~5 mg/mL daptomycin in lactated Ringer’s.
That structure suggests the patent’s technical message: daptomycin efficacy against biofilms improves when delivered in a specific resuscitation-fluid matrix and, in catheter contexts, paired with calcium and lock exposure.
Patent landscape: what can be inferred from claim architecture?
The claims’ parameterization (vehicle, calcium pairing, exposure window, concentration) typically indicates:
- the inventors saw route- and matrix-dependent activity rather than only antibiotic potency alone
- the claims are crafted to capture clinical protocols (lock times, flush steps) that are difficult to replicate without changing more than one variable
From a landscape perspective, this means the competitive space is likely split into:
- formulations that change vehicle (avoid lactated Ringer’s)
- formulations that omit or replace calcium (avoid daptomycin + calcium exposure)
- protocols that change exposure time (avoid ~30 minutes and/or ~18 hours)
- protocols that change concentration (avoid ≥1 mg/mL and ≥5 mg/mL; avoid about 5 mg/mL)
- workflows that remove lock therapy structure and related steps (avoid catheter-lock or heparin flush workflow)
Design-around map (how competitors typically avoid specific dependent limitations)
Below is a direct mapping from dependent-claim constraints to potential “escape” strategies that target claim elements rather than the antibiotic generally.
If using lactated Ringer’s is a risk
- Avoid lactated Ringer’s as the vehicle for the daptomycin solution used against biofilms (Claim 1; Claim 15; Claim 19; Claim 20).
If catheter lumen lock is a risk
- Avoid catheter lock therapy exposure structure for inner luminal surfaces (Claim 12), or avoid the lock-time parameter about 18 hours (Claim 14).
If concentration thresholds are a risk
- Avoid formulations at or above ≥1 mg/mL (Claim 8) or ≥5 mg/mL (Claim 9).
- Avoid “about 5 mg/mL” targets that are explicitly recited (Claims 13, 17, 19).
If calcium pairing is a risk
- Avoid “solution comprising daptomycin and calcium,” and avoid “physiological concentration of calcium” (Claim 10 and Claim 13).
If protocol workflows are a risk
- Avoid adding a heparin flush in the sequence with catheter lock biofilm treatment (Claim 16).
If outcome-based limitations are a risk
- Claims that require “does not reoccur” (Claim 4) are hard to argue around clinically; many competitors instead accept recurrence risk and do not promise the “no reoccurrence” outcome in practice.
Where validity or enforcement pressure would concentrate (claim drafting signals)
Even without examining the written description and file history, claim drafting signals where disputes tend to concentrate:
- Outcome limitation in Claim 4: “does not reoccur” is vulnerable because it depends on study design and follow-up duration.
- Parameter strictness: “about 30 minutes,” “at least 30 minutes,” “about 18 hours,” and “about 5 mg/mL” create a recurring question in enforcement about the meaning of “about.”
- Concentration and vehicle: the patent likely relies on the idea that vehicle matrix and calcium pairing alter biofilm activity; challengers often focus on whether those specifics were truly novel and supported.
- Device specificity: catheter inner luminal surface and catheter lock therapy is a structured clinical workflow, which tends to be enforceable when a hospital protocol matches the claim elements.
Key Takeaways
- US 8,003,673 claims two core approaches: daptomycin in lactated Ringer’s for biofilm treatment (Claim 1 and dependent claim set) and daptomycin + calcium for device and catheter surface biofilm exposure, including catheter lock therapy (Claims 10-14).
- Claim scope is controlled by vehicle (lactated Ringer’s), concentration (≥1 mg/mL; ≥5 mg/mL; about 5 mg/mL), exposure time (≥30 min; about 30 min; about 18 hours), dosing frequency (twice daily; ≥ four times daily), and catheter workflow (inner luminal lock therapy; heparin flush).
- The highest-risk overlap for competitors is the catheter protocol convergence: inner luminal exposure with ~5 mg/mL daptomycin in lactated Ringer’s (Claim 19) and catheter lock exposure with ~18 hours in the calcium-enabled device framework (Claim 12-14 plus Claim 13/15 patterns).
- Design-arounds that change only antibiotic dose without changing vehicle, calcium pairing, lock timing, or lumen workflow still risk dependent-claim coverage.
FAQs
1) Does Claim 1 require a specific concentration of daptomycin?
No. Claim 1 requires daptomycin in lactated Ringer’s applied to a biofilm, while concentration thresholds are added in dependent claims (Claims 8-9).
2) Is calcium required for the lactated Ringer’s embodiment?
Not in Claim 1. Calcium is explicit in Claim 10 and its dependent claim path, with physiological calcium specified in Claim 13. Claim 19 specifically recites lactated Ringer’s and ~5 mg/mL daptomycin for a catheter lumen context.
3) What is the only explicitly stated catheter lock exposure duration?
About 18 hours is recited in Claim 14.
4) Which dependent claims contain the largest concentration risk markers for formulation developers?
Claims 8 (≥1 mg/mL), 9 (≥5 mg/mL), 13 (~5 mg/mL with calcium), 17 (~5 mg/mL), and 19 (~5 mg/mL).
5) What step in the catheter protocol is explicitly required in a dependent claim?
A heparin flush is required by Claim 16 (in the Claim 11 catheter framework).
References
[1] United States Patent 8,003,673. (Title/assignee not provided in prompt). Claims as provided in user input.
